Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 2/20 | 0.85 |
| ▸ | HTR6 | P50406 | 2/20 | 0.85 |
| ▸ | HTR5A | P47898 | 1/20 | 0.85 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.61 |
| ▸ | MEN1 | O00255 | 4/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.61 |
| ▸ | TSHR | P16473 | 3/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.61 |
| ▸ | LMNA | P02545 | 3/20 | 0.61 |
| ▸ | USP2 | O75604 | 2/20 | 0.61 |
| ▸ | TP53 | P04637 | 2/20 | 0.61 |
| ▸ | MAPT | P10636 | 2/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.61 |
| ▸ | RGS12 | O14924 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | HTR1A | P08908 | 2/20 | 0.61 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.61 |
| ▸ | DRD2 | P14416 | 2/20 | 0.61 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14246888 | 1.00 | HTR7 (0.85) | HTR7HTR6HTR5ACYP2D6MEN1 | |
| SCHEMBL844523 | 0.92 | HTR7 (1.00) | HTR7HTR6HTR5ACYP2D6MEN1 | |
| SCHEMBL11732257 | 0.87 | HTR7 (0.74) | HTR7HTR6HTR5ACYP2D6MEN1 | |
| SCHEMBL11732263 | 0.87 | HTR7 (0.74) | HTR7HTR6HTR5ACYP2D6MEN1 | |
| SCHEMBL11732254 | 0.87 | HTR7 (0.74) | HTR7HTR6HTR5ACYP2D6MEN1 | |
| SCHEMBL10677158 | 0.85 | HTR7 (0.76) | HTR7HTR6HTR5ACYP2D6MEN1 | |
| SCHEMBL10677162 | 0.85 | HTR7 (0.76) | HTR7HTR6HTR5ACYP2D6MEN1 | |
| SCHEMBL10677155 | 0.85 | HTR7 (0.76) | HTR7HTR6HTR5ACYP2D6MEN1 | |
| SCHEMBL8209067 | 0.84 | HTR2B (0.84) | HTR7HTR6HTR5ACYP2D6MEN1 | |
| SCHEMBL10998929 | 0.83 | HTR7 (0.62) | HTR7HTR6HTR5ACYP2D6MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 186 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1776955-B1 | Medical use and composition for the treatment of lipid and glucose metabolism disorders | VEROSCIENCE LLC (US) | 2012-08-15 | — | — | EP | claimed |
| EP-1275392-B1 | Prolactin inhibiting or stimulating compounds to regulate the immune function | GEN HOSPITAL DOING BUSINESS AS (US) | 2009-08-26 | — | — | EP | claimed |
| EP-0934069-B1 | METHOD AND COMPOSITION FOR THE TREATMENT OF LIPID AND GLUCOSE METABOLISM DISORDERS | PLIVA ISTRAZIVANJE I RAZVOJ D (HR) | 2006-11-08 | — | — | EP | claimed |
| US-6855707-B2 | Method for the treatment of lipid and glucose metabolism disorders | PLIVA D.D. (HR) | 2005-02-15 | — | — | US | claimed |
| EP-0772396-B1 | METHOD OF REGULATING IMMUNE FUNCTION | GEN HOSPITAL CORP (US) | 2003-09-10 | — | — | EP | claimed |
| EP-1275392-A2 | Prolactin inhibiting or stimulating compounds to regulate the immune function | The General Hospital doing business as Massachusetts General Hospital (US) | 2003-01-15 | — | — | EP | claimed |
| US-5872127-A | Method of regulating immune function | THE GENERAL HOSPITAL CORPORATION/BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY (US) | 1999-02-16 | — | — | US | claimed |
| US-5866584-A | ADMINISTRATION OF A DOPAMINE AGONIST, OVER A LIMITED PERIOD AT A TIME OF DAY DEPENDENT ON THE NORMAL CIRCADIAN RHYTHM OF INSULIN RESISTANT AND INSULIN SENSITIVE MEMBERS OF A SIMILAR SPECIES. | THE BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (US) | 1999-02-02 | — | — | US | claimed |
| EP-0440333-B1 | Use of prolactin-inhibiting compounds for resetting the prolactin circadian rhythm | UNIV LOUISIANA STATE (US) | 1998-12-23 | — | — | EP | claimed |
| US-5712265-A | ANTIDIABETIC AGENTS AND METABOIC AGGENTS | THE GENERAL HOSPITAL CORPORATION (US) | 1998-01-27 | — | — | US | claimed |
| EP-0764026-A4 | ADMINISTRATION OF PIRENZEPINE, METHYL SCOPOLAMINE AND OTHER MUSCARINIC RECEPTOR ANTAGONISTS FOR TREATMENT OF LIPID METABOLISM DISORDERS | ERGO SCIENCE INC (US) | 1997-12-29 | — | — | EP | claimed |
| US-5696128-A | Method of regulating immune function | THE BOARD OF SUPERVISORS OF LOUISIANA UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (US) | 1997-12-09 | — | — | US | claimed |
| US-5668155-A | ALTERING LIPID METABOLISM IN VERTEBRATES FOR REDUCTION OF FATS | THE GENERAL HOSPITAL CORPORATION (US) | 1997-09-16 | — | — | US | claimed |
| EP-0764026-A1 | ADMINISTRATION OF PIRENZEPINE, METHYL SCOPOLAMINE AND OTHER MUSCARINIC RECEPTOR ANTAGONISTS FOR TREATMENT OF LIPID METABOLISM DISORDERS | ERGO SCIENCE INCORPORATED (US) | 1997-03-26 | — | — | EP | claimed |
| WO-1995035110-A1 | ADMINISTRATION OF PIRENZEPINE, METHYL SCOPOLAMINE AND OTHER MUSCARINIC RECEPTOR ANTAGONISTS FOR TREATMENT OF LIPID METABOLISM DISORDERS | ERGO SCIENCE INCORPORATED (US) | 1995-12-28 | — | — | WO | claimed |
| EP-0440333-A2 | Dopamine agonists for treating type II diabetes | LOUISIANA STATE UNIVERSITY AGRICULTURAL AND MECHANICAL COLLEGE (US) | 1991-08-07 | — | — | EP | claimed |
| JP-7048257-A | — | — | None | — | — | JP | disclosed |
| US-11963964-B2 | Small molecules for mouse satellite cell proliferation | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2024-04-23 | — | — | US | disclosed |
| JP-H0748257-A | THERAPEUTIC AGENT FOR TYPE II DIABETES | UNIV LOUISIANA STATE | 1995-02-21 | — | — | JP | disclosed |
| WO-1994015211-A1 | IMPROVED METHODS FOR THE DETERMINATION AND ADJUSTMENT OF PROLACTIN DAILY RHYTHMS | ERGO SCIENCE INCORPORATED (US) | 1994-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11963964-B2 | Small molecules for mouse satellite cell proliferation | MKI67, MYLK2, MYH2 | HTR7 4419/4885HTR6 4177/4885HTR5A 4722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.